antipyrine has been researched along with Myocardial Infarction in 19 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 9.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "The effect of edaravone, a free radical scavenger, on long-term prognosis and its efficacy with regards to scavenging injurious free radicals in patients with acute myocardial infarction (AMI) was examined." | 9.12 | Long-term efficacy of edaravone in patients with acute myocardial infarction. ( Fukuda, M; Hokamaki, J; Kaikita, K; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2006) |
| "This clinical pilot study was a randomized, controlled, open-label study in 80 patients with acute myocardial infarction and was designed to examine the effects of a novel free radical scavenger, edaravone." | 9.11 | Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. ( Arai, H; Fukuda, M; Hida, S; Hokamaki, J; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2004) |
| "In the present study, we investigated whether combination therapy of low-dose benidipine with the potent free radical scavenger edaravone has a cardioprotective effect against isoproterenol (ISO)-induced myocardial infarction (MI) in Wistar rats." | 7.83 | Edaravone, a potent free radical scavenger and a calcium channel blocker attenuate isoproterenol induced myocardial infarction by suppressing oxidative stress, apoptotic signaling and ultrastructural damage. ( Akhtar, M; Akhtar, MS; Ali, J; Haque, SE; Hassan, MQ; Najmi, AK, 2016) |
| "To explore the effect of edaravone on bone marrow mesenchymal stem cells (BMSCs) transplanted to treat acute myocardial infarction (AMI) and the underlying mechanism." | 7.83 | Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model. ( Gu, TX; Li-Ling, J; Qi, X; Sun, XJ; Wang, C; Wang, XB; Zhang, GW, 2016) |
| "The present study was designed to evaluate the cardioprotective potential of edaravone on oxidative stress, anti-apoptotic, anti-inflammatory and ultrastructure findings in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 7.81 | Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence. ( Akhtar, M; Akhtar, MS; Ali, J; Haque, SE; Hassan, MQ; Najmi, AK, 2015) |
| "Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure." | 5.14 | Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. ( Chitose, T; Fukuda, M; Kaikita, K; Nagata, T; Nagayoshi, Y; Nakamura, Y; Nako, H; Ogawa, H; Ogura, Y; Ohba, K; Shimomura, H; Soejima, H; Sugiyama, S; Tsujita, K; Yamada, Y; Yamaguchi, M; Yamashita, T, 2009) |
| "The effect of edaravone, a free radical scavenger, on long-term prognosis and its efficacy with regards to scavenging injurious free radicals in patients with acute myocardial infarction (AMI) was examined." | 5.12 | Long-term efficacy of edaravone in patients with acute myocardial infarction. ( Fukuda, M; Hokamaki, J; Kaikita, K; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2006) |
| "This clinical pilot study was a randomized, controlled, open-label study in 80 patients with acute myocardial infarction and was designed to examine the effects of a novel free radical scavenger, edaravone." | 5.11 | Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. ( Arai, H; Fukuda, M; Hida, S; Hokamaki, J; Kawano, H; Nagayoshi, Y; Nakamura, Y; Ogawa, H; Sakamoto, T; Shimomura, H; Tsujita, K; Yamashita, T; Yoshimura, M, 2004) |
| "In the present study, we investigated whether combination therapy of low-dose benidipine with the potent free radical scavenger edaravone has a cardioprotective effect against isoproterenol (ISO)-induced myocardial infarction (MI) in Wistar rats." | 3.83 | Edaravone, a potent free radical scavenger and a calcium channel blocker attenuate isoproterenol induced myocardial infarction by suppressing oxidative stress, apoptotic signaling and ultrastructural damage. ( Akhtar, M; Akhtar, MS; Ali, J; Haque, SE; Hassan, MQ; Najmi, AK, 2016) |
| "To explore the effect of edaravone on bone marrow mesenchymal stem cells (BMSCs) transplanted to treat acute myocardial infarction (AMI) and the underlying mechanism." | 3.83 | Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model. ( Gu, TX; Li-Ling, J; Qi, X; Sun, XJ; Wang, C; Wang, XB; Zhang, GW, 2016) |
| "The present study was designed to evaluate the cardioprotective potential of edaravone on oxidative stress, anti-apoptotic, anti-inflammatory and ultrastructure findings in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 3.81 | Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence. ( Akhtar, M; Akhtar, MS; Ali, J; Haque, SE; Hassan, MQ; Najmi, AK, 2015) |
| "It has been shown, that antipyrine, nifedipine, diazepam pharmacokinetics changes in different ways after myocardial infarction." | 3.68 | [Pharmacokinetics of antipyrine, nifedipine and diazepam in experimental myocardial infarct]. ( Anan'ev, EA; Grek, OR; Kolpakov, MA; Sharapov, VI, 1992) |
| "Four caffeine-treated rats had histologic evidence of acute myocardial infarction which was not found in any of the other rats." | 1.26 | Cardiovascular lesions in Sprague-Dawley rats induced by long-term treatment with caffeine. ( Johansson, S, 1981) |
| "In six patients without cardiac failure the plasma concentrations of lignocaine rose progressively during the infusion and the mean lignocaine half life was 4." | 1.26 | Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. ( Adjepon-Yamoah, KK; Prescott, LF; Talbot, RG, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, G | 1 |
| Sun, Y | 1 |
| Wang, Y | 1 |
| Li, X | 1 |
| Li, T | 1 |
| Su, S | 1 |
| Xu, L | 1 |
| Shen, H | 1 |
| Hassan, MQ | 2 |
| Akhtar, MS | 2 |
| Akhtar, M | 2 |
| Ali, J | 2 |
| Haque, SE | 2 |
| Najmi, AK | 2 |
| Zhang, GW | 1 |
| Gu, TX | 1 |
| Sun, XJ | 1 |
| Wang, C | 1 |
| Qi, X | 1 |
| Wang, XB | 1 |
| Li-Ling, J | 1 |
| Nakamura, Y | 3 |
| Yamada, Y | 1 |
| Shimomura, H | 3 |
| Nagayoshi, Y | 3 |
| Tsujita, K | 3 |
| Yamashita, T | 3 |
| Fukuda, M | 3 |
| Ohba, K | 1 |
| Nako, H | 1 |
| Ogura, Y | 1 |
| Chitose, T | 1 |
| Yamaguchi, M | 1 |
| Nagata, T | 1 |
| Soejima, H | 1 |
| Kaikita, K | 2 |
| Sugiyama, S | 1 |
| Ogawa, H | 3 |
| Rajesh, KG | 1 |
| Sasaguri, S | 1 |
| Suzuki, R | 1 |
| Maeda, H | 1 |
| Kawano, H | 2 |
| Hokamaki, J | 2 |
| Hida, S | 1 |
| Sakamoto, T | 2 |
| Yoshimura, M | 2 |
| Arai, H | 1 |
| Onimaru, S | 1 |
| Nakamura, K | 1 |
| Kariyazono, H | 1 |
| Ikeda, R | 1 |
| Ueno, T | 1 |
| Fukumoto, Y | 1 |
| Yabuki, A | 1 |
| Sakata, R | 1 |
| Yamada, K | 1 |
| Onogi, H | 1 |
| Minatoguchi, S | 1 |
| Chen, XH | 1 |
| Bao, N | 1 |
| Kobayashi, H | 1 |
| Misao, Y | 1 |
| Yasuda, S | 1 |
| Yamaki, T | 1 |
| Maruyama, R | 1 |
| Uno, Y | 1 |
| Arai, M | 1 |
| Takemura, G | 1 |
| Fujiwara, H | 1 |
| Patanè, S | 1 |
| Marte, F | 1 |
| Di Bella, G | 1 |
| Chiofalo, S | 1 |
| Currò, A | 1 |
| Coglitore, S | 1 |
| Johansson, S | 1 |
| Kettner, W | 1 |
| Banditt, P | 1 |
| Walther, H | 1 |
| George, S | 1 |
| Vannozi, Z | 1 |
| Breckenridge, A | 1 |
| Massion, W | 1 |
| Blümel, G | 1 |
| Erhardt, W | 1 |
| Krueger, P | 1 |
| Petrowicz, O | 1 |
| Wendt, P | 1 |
| Heinkelmann, W | 1 |
| Prescott, LF | 1 |
| Adjepon-Yamoah, KK | 1 |
| Talbot, RG | 1 |
| Sharapov, VI | 1 |
| Grek, OR | 1 |
| Anan'ev, EA | 1 |
| Kolpakov, MA | 1 |
| Utley, J | 1 |
| Carlson, EL | 1 |
| Hoffman, JI | 1 |
| Martinez, HM | 1 |
| Buckberg, GD | 1 |
4 trials available for antipyrine and Myocardial Infarction
| Article | Year |
|---|---|
Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Biomarkers; Chemokine CCL2; Edaravone; Female; Fre | 2009 |
Effects of edaravone on reperfusion injury in patients with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Antipyrine; Creatine Kinase; Creatine Kinase, MB Form; Edaravo | 2004 |
Long-term efficacy of edaravone in patients with acute myocardial infarction.
Topics: Acute Disease; Antipyrine; Arrhythmias, Cardiac; Edaravone; Free Radical Scavengers; Humans; Myocard | 2006 |
Oral anticoagulants--the totem and the taboo.
Topics: Animals; Anticoagulants; Antipyrine; Barbiturates; Blood Coagulation; Chloral Hydrate; Clinical Tria | 1976 |
15 other studies available for antipyrine and Myocardial Infarction
| Article | Year |
|---|---|
Local administration of lactic acid and a low dose of the free radical scavenger, edaravone, alleviates myocardial reperfusion injury in rats.
Topics: Animals; Antipyrine; Apoptosis; Dose-Response Relationship, Drug; Edaravone; Free Radical Scavengers | 2013 |
Edaravone protects rats against oxidative stress and apoptosis in experimentally induced myocardial infarction: Biochemical and ultrastructural evidence.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; C-Reactive Protein; Caspase 3; Creatine Kinase, MB For | 2015 |
Edaravone, a potent free radical scavenger and a calcium channel blocker attenuate isoproterenol induced myocardial infarction by suppressing oxidative stress, apoptotic signaling and ultrastructural damage.
Topics: Animals; Antipyrine; Apoptosis; C-Reactive Protein; Calcium Channel Blockers; Caspase 3; Dihydropyri | 2016 |
Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model.
Topics: Animals; Antipyrine; Apoptosis; Cell Movement; Cells, Cultured; Cytokines; Disease Models, Animal; E | 2016 |
Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Antioxidants; Antipyrine; Atractyloside; Blo | 2003 |
Inhibitory effects of edaravone on the production of tumor necrosis factor-alpha in the isolated heart undergoing ischemia and reperfusion.
Topics: Analysis of Variance; Animals; Antipyrine; Blood Pressure; Blotting, Western; Edaravone; Free Radica | 2006 |
Edaravone reduces myocardial infarct size and improves cardiac function and remodelling in rabbits.
Topics: Animals; Antipyrine; Blood Pressure; Edaravone; Enzyme Inhibitors; Free Radical Scavengers; Gentisat | 2006 |
Acute myocardial infarction and Kounis syndrome.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Drug Hypersensitivity; Female; Flavoxate; | 2009 |
Cardiovascular lesions in Sprague-Dawley rats induced by long-term treatment with caffeine.
Topics: Acetaminophen; Animals; Antipyrine; Caffeine; Cardiovascular Diseases; Heart; Male; Myocardial Infar | 1981 |
[Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency].
Topics: Aged; Antipyrine; Dose-Response Relationship, Drug; Female; Half-Life; Heart Diseases; Heart Valve D | 1983 |
Myocardial infarction induced by migraine therapy.
Topics: Acetaminophen; Adult; Antipyrine; Chloral Hydrate; Coronary Vasospasm; Drug Combinations; Female; Hu | 1995 |
[The effect of proteinase inhibitors in the early stage after experimental myocardial infarction (author's transl)].
Topics: Animals; Antipyrine; Aprotinin; Blood Cell Count; Blood Platelets; Cats; Creatine Kinase; Disease Mo | 1976 |
Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Topics: Adult; Aged; Antipyrine; Half-Life; Heart Failure; Humans; Lidocaine; Male; Middle Aged; Myocardial | 1976 |
[Pharmacokinetics of antipyrine, nifedipine and diazepam in experimental myocardial infarct].
Topics: Animals; Antipyrine; Cytochrome P-450 Enzyme System; Diazepam; Hydroxylation; Male; Microsomes, Live | 1992 |
Total and regional myocardial blood flow measurements with 25 micron, 15 micron, 9 micron, and filtered 1-10 micron diameter microspheres and antipyrine in dogs and sheep.
Topics: Adenosine Triphosphate; Animals; Antipyrine; Aorta; Blood Flow Velocity; Constriction; Coronary Circ | 1974 |